Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dice Therapeutics Inc (NQ: DICE )

32.96 +0.38 (+1.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 338,295
Open 32.61
Bid (Size) 20.37 (10)
Ask (Size) 52.60 (2)
Prev. Close 32.58
Today's Range 32.00 - 33.08
52wk Range 12.63 - 45.99
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
 
Via Benzinga

Performance

YTD
+5.20%
+5.20%
1 Month
-12.87%
-12.87%
3 Month
+25.99%
+25.99%
6 Month
+1.76%
+1.76%
1 Year
+124.37%
+124.37%

More News

Read More
Recap: DICE Therapeutics Q1 Earnings
Via Benzinga
Over $40M Bet On 89bio? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Where DICE Therapeutics Stands With Analysts
Via Benzinga
DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics to Participate in the Bank of America Securities 2023 Healthcare Conference
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting
From DICE Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
Via Benzinga
DICE Therapeutics to Participate at Upcoming Investor Conferences
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From DICE Therapeutics, Inc.
Via GlobeNewswire
These 3 Stocks Are Crushing the Market. Wall Street Thinks They Can Soar at Least 78% Higher.
Via The Motley Fool
Blue Star (NASDAQ: BSFC) Insiders Are Buying Stock
Via Benzinga
DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights
From DICE Therapeutics, Inc.
Via GlobeNewswire
DICE Therapeutics to Present at Upcoming Investor Conferences
From DICE Therapeutics, Inc.
Via GlobeNewswire
Around $60 Million Bet On DICE Therapeutics? 3 Stocks Insiders Are Buying
Via Benzinga
Jim Cramer Says People Are Betting Against Stock Up 84% This Year: It Could Be An 'Up Big, Down Big Situation'
Via Benzinga
DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From DICE Therapeutics, Inc.
Via GlobeNewswire
Bear Market Hits New Lows, But Stocks Rebound After Hot CPI Inflation Report: Weekly Review
Via Investor's Business Daily
DICE Announces Pricing of Upsized Public Offering of Common Stock
From DICE Therapeutics, Inc.
Via GlobeNewswire
Why Laser Photonics Shares Jumped By Around 44%; Here Are 72 Biggest Movers From Yesterday
Via Benzinga
DICE Announces Proposed Public Offering of Common Stock
From DICE Therapeutics, Inc.
Via GlobeNewswire
Nasdaq Drops 150 Points; AZZ Shares Plummet
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.